Failure of etanercept and methotrexate in combination to surpass etanercept alone in psoriatic arthritis (PsA) – what about the joint counts?

This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Letter to the Editor Source Type: research

Related Links:

A treat-to-target approach to psoriatic arthritis has emerged as a topic of interest following successful application of this treatment paradigm to rheumatoid arthritis. In psoriatic arthritis, this has been examined in one randomized trial to date showing benefits of a tight control treatment strategy over standard care. Nonetheless, international treatment recommendations have called for clinicians to aim for a target of remission or low disease activity, although little or no consensus exists on how to measure these targets. An ideal measure to define a treatment target should be able to address all the disease domains ...
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: Source Type: research
ConclusionsThis set of standards of care should help improve quality of care in PsA patients.ResumenObjetivoGenerar una norma de calidad para el manejo del paciente con artritis psoriásica (APs).MétodosMetodología cualitativa que incluyó: 1) dos grupos focales (uno con pacientes con APs y otro con especialistas no reumatólogos implicados en su cuidado); 2) revisión de la literatura publicada sobre documentos en el ámbito de la calidad asistencial en APs; 3) reunión de grupo nominal donde 15 expertos reumatólogos generaron, de forma consensuada, una serie de cri...
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
PMID: 31399996 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Associations between gluten intake and psoriasis, psoriatic arthritis and atopic dermatitis are poorly understood.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
AbstractMethotrexate (MTX) is a frequently used anti-psoriatic drug that is commonly recommended in international psoriasis guidelines. It is effective in treating skin lesions, nail changes and psoriatic arthritis. In 2017 a prospective, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, commonly known as the METOP trial, was published assessing the effectiveness and safety of subcutaneous administration of methotrexate. Because trial data do not always relate to real-life data with unselected patient populations, we wanted to determine whether the data obtained in the METOP-trial correspond to real...
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
The aim of the current study was to investigate the long non-coding RNA (lncRNA) expression profiles in psoriatic arthritis (PSA) patients by RNA sequencing, and to further explore potential biomarkers that we...
Source: BMC Immunology - Category: Allergy & Immunology Authors: Tags: Research article Source Type: research
Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases of unclear etiology. There is evidence, that genetic, immunologic, and environmental factors contribute to its pathology. Autoimmune oophoritis has been proposed as one of the possible etiologies of diminished ovarian reserve. Pro-inflammatory cytokine - tumor necrosis factor alpha (TNF α) is implicated in the pathogenesis of oophoritis and psoriasis. Certolizumab is an anti-TNFα monoclonal antibody studied now in the treatment of psoriasis.
Source: Maturitas - Category: Primary Care Authors: Tags: LBP01 Source Type: research
Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease. Interleukin (IL)-17 plays a major role in the development of both psoriasis and PsA. IL-23 is important in the proliferation and maintenance of IL-17, and therefore, cytokines of the IL-23/IL-17 axis attracted much interest as therapeutic targets in psoriasis and PsA. Therapeutic agents targeting the cytokine IL-23/IL-17 axis have been proved very effective in psoriasis and PsA, some are already in the therapeutic armament...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
We describe the percentage of acute anterior uveitis (AAU) in a diverse group of SpA patients seen at one academic setting and compare demographic and clinical characteristics according to the presence of uveitis. We conducted a retrospective study of patients with SpA and AAU (January 2016 –June 2017). Patients were identified using ICD-10 and administrative claim codes, diagnoses were confirmed through chart review. Extracted data included demographics, laboratory, clinical data, treatment and Routine Assessment of Patient Index Data 3 (RAPID3) scores based on Multidimensional Heal th Assessment Questionnaire (MDHA...
Source: Rheumatology International - Category: Rheumatology Source Type: research
This study described treatment patterns in a psoriatic arthritis (PsA) patient registry for new or ongoing tumor necrosis factor inhibitor (TNFi) monotherapy, conventional synthetic disease-modifying antirheumatic drug (csDMARD) monotherapy, or TNFi/csDMARD combination therapy. This retrospective analysis included adults with PsA who enrolled in the Corrona PsA/spondyloarthritis registry between March 21, 2013 (registry initiation), and January 31, 2017, and received an approved TNFi and/or csDMARD as “existing use” starting before registry entry or “initiated use” starting on/after registry entry. ...
Source: Rheumatology International - Category: Rheumatology Source Type: research
More News: Arthritis | Enbrel | Methotrexate | Psoriatic Arthritis | Rheumatology